NCT04667897View on ClinicalTrials.gov

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

July 13, 2022

Study Completion Date

July 13, 2022

Conditions
Branch Retinal Vein Occlusion
Interventions
DRUG

601 1.25mg

Solution for injection (intravitreal use)

DRUG

Ranibizuman 0.5 mg

Solution for injection (intravitreal use)

Trial Locations (1)

100730

BeiJing Hospital, Beijing

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY

NCT04667897 - 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) | Biotech Hunter | Biotech Hunter